



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Doddabele L. Madhavi, *et al.*
Serial No. : 10/735,335
Filed: : December 12, 2003
For: : Bioavailable Carotenoid-Cyclodextrin Formulations
For Soft-Gels And Other
Encapsulation Systems
TC/AU : 1623
Examiner : Matthew L. Fedowitz
Attorney Docket No. : BIO 2-016

HONORABLE COMMISSIONER FOR PATENTS
MAIL STOP NO FEE AMENDMENT
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


Sir:

Copies of the art were submitted previously along with a listing of the art. Unfortunately, form PTO/SB/08B had a field issue that prevented the full titles of some of the citations from being completely visible when printed. For this Applicant apologizes to the Examiner. The form with complete citations accompanies this IDS and its entry respectfully is requested.

Respectfully submitted,

Date:

28 March 2005




Jerry K. Mueller, Jr.
Reg. No. 27,576
MUELLER AND SMITH, L.P.A.
Mueller-Smith Building
7700 Rivers Edge Drive
Columbus, Ohio 43235-1355
Tel.: 614-436-0600
Fax: 614-436-0057
email: smueller@muellersmith.com

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents, Box 1450, Alexandria, VA 20313-1450 on March 29, 2005.


Jane Keeney



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/735,335				
	Filing Date	December 12, 2003			
	First Named Inventor	Doddabele L. Madhavi			
	Art Unit	1633			
	Examiner Name	Matthew L. Fedowitz			
Sheet	2	of	3	Attorney Docket Number	BIO 2-016

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1.	SKALKO-BASNET, et al., "Liposomes Containing Drug and Cyclodextrin Prepared by the One-Step Spray-Drying Method", Drug Dev Ind Pharm. 2000 Dec;26(12) :1279-84.	
	2.	YU, et al., "Effect of camphor/cyclodextrin complexation on the stability of O/W/O multiple emulsions", Int J Pharm 2003 Aug 11;261(1-2):1-8.	
	3.	VALERO, et al., "Ternary naproxen: beta-cyclodextrin:polyethylene glycol complex formation", Int J Pharm 2003 Oct 20; 265(1-2):141-9.	
	4.	VEIGA, et al., "Influence of surfactants (present in the dissolution media) on the release behaviour of tolbutamide from its inclusion complex with beta-cyclodextrin", Eur J. Pharm Sci. 2000 Jan;9(3) :291-9.	
	5.	TONNESEN, et al., "Studies of curcumin and curcuminoids, XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability", Int J Pharm. 2002 Sep 5;244(1-2) :127-35.	
	6.	MURA, et al., "Effects of the host cavity size and the preparation method on the physicochemical properties of ibuprofen-cyclodextrin systems", Drug Dev Ind Pharm.1999 Mar;25 (3) :279-87.	
	7.	ALEXANDER, et al., "Chiral discrimination in cyclodextrin complexes of amino acid derivatives: beta-cyclodextrin/N-acetyl-L-phenylalanine and N-acetyl-D-phenylalanine complex", Proc Natl Acad Sci USA. 2002 Apr 16;99(8) :5115-20. Epub 2002 Apr 09.	
	8.	VAKILY, et al., "Inclusion complexation of heptakis (2, 6-di-O-ethyl)-beta-cyclodextrin with tiaprofenic acid: pharmacokinetic consequences of a pH-dependent release and stereoselective dissolution", J Pharm Sci. 1995 Aug;84 (8) :1014-9.	
	9.	MURA, et al., "Influence of the Preparation Method on the Physicochemical Properties of Binary Systems of Econazole with Cyclodextrins", Int Journ of Pharm 193 (1999) 85-95.	
	10.	AHSAN, et al., "Mutual Inhibition of the Insulin Absorption-Enhancing Properties of Dodecylmaltoside and Dimethyl-B-Cyclodextrin Following Nasal Administration", Pharm Res 2001 May;18 (5): 608-14.	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/735,335		
		Filing Date	December 12, 2003		
		First Named Inventor	Doddabele L. Madhavi		
		Art Unit	1633		
		Examiner Name	Matthew L. Fedowitz		
Sheet	3	of	3	Attorney Docket Number	BIO 2-016

NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	11.	LOCKWOOD, et al., "Improved Aqueous Solubility of Crystalline Astaxanthin (3,3'-dihydroxy-B, B-carotene - 4,4"-dione) by Captisol (Sulfobutyl Ether B-Cyclodextrin)", Jour of Pharm Sci, Vol 92, 922-926 (2003).	
	12.	SPIRICHEV, et al., "[Study of bioavailability of different forms of synthetic beta-carotene in volunteers]", Vop Pitn. 1996(6) :22-6. Article in Russian.	
	13.	MIYAKE, et al., "Improvement of solubility and oral bioavailability of rutin by complexation with 2-hydroxypropyl-beta-cyclodextrin", Pharm Dev technol 2000;5(3) :399-407.	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



1FW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/735,335	
	Filing Date	December 12, 2003	
	First Named Inventor	Doddabele L. Madhavi	
	Art Unit	1623	
	Examiner Name	Matthew L. Fedowitz	
Total Number of Pages in This Submission	4	Attorney Docket Number	BIO 2-016

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Supplemental Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	Mueller and Smith, LPA		
Signature			
Printed name	Jerry K. Mueller, Jr.		
Date	March 29, 2005	Reg. No.	27,576

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or printed name	Jane Keeney	Date	March 29, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.